RxDoctor Payments Data

Christina Pauda

Family · Lubbock, TXNPI 1750093779

Payments from drug & device makers

$5,146in general payments, 2019–2025

Across 271 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$904
  • AbbVie$720
  • AstraZeneca$685
  • GSK$538
  • Johnson & Johnson$431
  • UCB, Inc.$404
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$5,09299%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen66$904
AbbVie36$720
AstraZeneca30$685
GSK29$538
Johnson & Johnson24$431
UCB, Inc.13$404
E.r. Squibb & Sons, L.L.C.18$353
Pfizer14$311
Radius Health, Inc.14$246
Novartis11$215
Sandoz7$179
Boehringer Ingelheim5$94
Organon2$27
Mylan Institutional Inc.1$22
Genentech USA, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,146 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$69,780
Medicare patients
133
Services billed
4,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept26$193,263
Humira(Cf) PenAdalimumab15$101,153
RinvoqUpadacitinib14$90,012
BenlystaBelimumab12$59,023
Hydroxychloroquine Sulfate191$3,969
MethotrexateMethotrexate Sodium280$3,599
Mycophenolate Mofetil34$2,448
Duloxetine Hcl121$2,063
Sulfasalazine DrSulfasalazine29$1,298
Azathioprine37$1,207
Leflunomide53$1,060
Sulfasalazine43$1,055
Gabapentin66$748
Celecoxib53$582
Tizanidine Hcl26$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$720$90,01214 claims
GSKBenlysta$538$59,02312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →